
Crown Prince and Vertex Pharmaceuticals CEO Discuss Medical Milestone and Future Collaborations
Manama: A telephone conversation took place between His Royal Highness Prince Salman bin Hamad Al Khalifa, the Crown Prince and Prime Minister, and Dr. Reshma Kewalramani, the CEO and President of Vertex Pharmaceuticals. During the call, significant medical achievements and future collaborations were discussed.
According to Bahrain News Agency, His Royal Highness highlighted Bahrain's recent medical milestone wherein the Kingdom successfully treated the world's first sickle cell disease patient outside the United States using Casgevy (exagamglogene autotemcel). This CRISPR-based gene-editing therapy was accomplished through advanced bone marrow transplantation technology.
His Royal Highness reaffirmed the importance of strengthening Bahrain's partnership with Vertex Pharmaceuticals, aiming to explore future opportunities that will bolster the Kingdom's health sector. This partnership is expected to enhance Bahrain's position as a leader in scientific and medical advancements.
Prince Salman emphasized Bahrain's commitment to collaborating with leading international specialized medical institutions, ensuring the Kingdom remains at the forefront of scientific progress. He stressed the importance of integrating cutting-edge treatments into the healthcare and rehabilitation services available to Bahrainis, underscoring this as a top priority for the Kingdom's health initiatives.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Gulf Insider
a day ago
- Gulf Insider
New Stem Cell Therapy Shows 'Promising' Results For Treating Hair Loss In Preclinical Trials
Researchers at the San Carlos Clinical Hospital in Madrid may have targeted a potential solution for hair loss. A recent study analyzed the effect of injecting mice's skin with stem cells from human fat — 'adipose-derived stem cells (ASCs)' — as a means of treating androgenetic alopecia (AGA), more commonly known as male- or female-pattern hair loss. The team found that male mice achieved the best hair regrowth after three weeks when they received low-dose ASCs, combined with an energy-boosting molecule called adenosine triphosphate (ATP). Low-dose and high-dose ASC treatments along with ATP led to no hair regrowth improvement in females, but medium-dose ASC plus ATP led to greater regrowth. The researchers concluded that hair regrowth was improved in 'all experimental groups' where male mice received stem cell solutions supplemented with ATP. Researchers at the San Carlos Clinical Hospital in Madrid may have targeted a potential solution for hair loss. (iStock) The findings were published in the journal Stem Cell Research & Therapy. Lead study author Dr. Eduardo López Bran — dermatologist and professor at The Complutense University of Madrid — shared his expectations for the study in an interview with Fox News Digital. 'We expected good results, but not such a high level of success,' he said. 'We're talking about a very high degree of hair regrowth in both male and female mice.' With appropriate doses, the researchers achieved 'very high percentages' of hair regrowth, noting that 100% of the male mice and up to 90% of the female mice regrew hair. With appropriate doses, the researchers achieved 'very high percentages' of hair regrowth, noting that 100% of the male mice and up to 90% of the female mice regrew hair. (Actual mice from the study not pictured.) (iStock) 'These results demonstrate that advanced therapies may represent a new therapeutic approach for many diseases for which no effective treatments are currently available,' Bran went on. 'Achieving such promising results in the preclinical phase with a completely novel approach to androgenetic alopecia — one that avoids chronic treatment and is also safe — is a significant scientific milestone.' 'We're talking about a very high degree of hair regrowth in both male and female mice.' The main limitation of the study was the thinness of mouse skin, Bran noted, which 'posed a challenge in administering the therapy.' 'This required the development of protocols to minimize experimental variability, and will be a key factor when studies in humans begin,' he said. 'Research advances are pointing toward possible solutions that, in the future, may offer long-lasting results without the need for continuous treatment to maintain benefits.' (iStock) These new findings should be 'interpreted with caution and scientific rigor,' Bran cautioned. 'Although the results in mice represent significant progress, it is also true that it is essential to wait for clinical benefits in humans to be confirmed.' The researcher encouraged those with androgenetic alopecia to continue consulting with their dermatologists and to follow prescribed treatments as research develops. 'It is important to remain hopeful. Research advances are pointing toward possible solutions that, in the future, may offer long-lasting results without the need for continuous treatment to maintain benefits,' Bran added. 'This study is small, and more research is needed on this method as a potential treatment option.' Looking ahead to human clinical trials, researchers are 'actively working' on confirming safety for men and women between 18 and 50 years old with moderate androgenetic alopecia, the researcher noted. 'If everything progresses as expected, the most optimistic timeline points to the treatment becoming available in approximately five years,' he said. Looking ahead to human clinical trials, researchers are 'actively working' on confirming safety for men and women between 18 and 50 years old with moderate androgenetic alopecia. (iStock) In a separate interview with Fox News Digital, Dr. Brendan Camp, M.D., a New York-based dermatologist who was not involved in the study, commented on the potential for this method. 'While not commercially available, this study suggests that injection of stem cells supplemented with ATP into scalp skin could potentially encourage hair regrowth in individuals with androgenetic alopecia,' he reiterated.


Gulf Insider
07-06-2025
- Gulf Insider
Ghana Reports Worst Monkeypox Outbreak Since 2022
Ghana has recorded 45 cases of monkeypox over the past month, marking the country's worst outbreak of the virus since 2022, according to the Ghana Health Service. No fatalities have been reported. The virus, which causes fever and a severe skin rash, has prompted authorities to implement a response plan that includes identifying, isolating, and treating patients, tracing contacts, vaccinating at risk healthcare workers, and launching a wide scale public awareness campaign. The Ghanaian government warned that case numbers are expected to rise in the coming days or weeks. Health authorities noted that the strain currently circulating in Ghana is considered less severe than the variant reported in Central Africa. Source Bahrain News Agency


Daily Tribune
02-06-2025
- Daily Tribune
MP pushes for jobless pay for freelancers
A proposal aiming to give self-employed Bahrainis a chance to draw jobless pay during bouts of ill-health has been tabled by MP Jalal Kadhem. His amendment to the 2006 Unemployment Insurance Decree would let freelancers and people running their own businesses voluntarily sign up for an insurance scheme currently reserved for employed workers. Those affected by illness or injury, unrelated to work, would become eligible for monthly payments equal to 60 per cent of their average earnings, capped at BD1,000, provided the medical condition lasts no fewer than 30 days. To claim the support, the person must be Bahraini, aged at least 18, registered in the voluntary insurance scheme, and dependent solely on their profession for income. The incapacity has to be medically certified by authorised committees. Serious hurdles Kadhem pointed out clearly in his explanatory note how people working for themselves face serious hurdles whenever sickness puts their livelihoods on pause. 'These individuals face major challenges in the event of a temporary health condition that prevents them from performing their work,' he wrote. 'This leads to a complete halt in monthly income, negatively affecting the morale, finances, and mental wellbeing of the entire family.' The proposal creates a new category of 'voluntarily insured person', covering freelancers and self-employed citizens who join the voluntary social insurance scheme.